Q3 2025 ImmuCell Corp Earnings Call Transcript
Key Points
- ImmuCell Corp (ICCC) reported a significant improvement in net income, achieving $1.8 million during the first nine months of 2025 compared to a net loss of $2.7 million in the same period of 2024.
- Gross margins improved substantially, increasing to 43% during the third quarter of 2025 from 26% in the third quarter of 2024.
- The company successfully eliminated its order backlog and rebuilt inventory and distribution channels, positioning itself well for future sales.
- Domestic sales showed positive momentum, increasing by 2% during the third quarter of 2025 compared to the same quarter in 2024.
- The company is poised for growth with the onboarding of a new CEO, Olivier te Boekhorst, who brings extensive experience in animal health and a focus on customer-centric strategies.
- Total product sales decreased by 8% during the third quarter of 2025 compared to the third quarter of 2024, primarily due to the timing of shipments and allocation of short supply.
- International sales, particularly to Canada, were down during the third quarter of 2025 compared to the same period in 2024.
- The company anticipates continued difficult year-over-year sales comparisons due to the backlog fulfillment in prior periods.
- Despite improvements, the company is still awaiting FDA approval for its Re-Tain product, which is crucial for addressing market needs in subclinical mastitis treatment.
- The company faces challenges in balancing production with cash management, as indicated by high levels of work-in-progress inventory, particularly frozen colostrum.
Good morning, and welcome to the ImmuCell Corporation reports third-quarter ended September 30, 2025, unaudited financial results conference call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Joe Diaz of Lytham Partners. Please go ahead.
Thank you, Rocco. Good morning, and welcome to everyone. As Rocco indicated, my name is Joe Diaz with Lytham Partners. We're the Investor Relations consulting firm for ImmuCell. I want to thank all of you for joining us today to discuss the unaudited financial results for the third-quarter ended September 30, 2025.
Listeners are cautioned that statements made by management during the course of this call include forward-looking statements, which include any statements that refers to the future events or expected future results or predictions about steps the company plans to take in the future.
These statements are not guarantees of performance and are subject to risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
